The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 "harvest" have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecules (Basel, Switzerland) Switzerland), 2018-02, Vol.23 (3), p.533
Hauptverfasser:	de la Torre, Beatriz G, Albericio, Fernando
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino acids Antibodies API Arthritis Asthma Biological products Biological Products - chemistry Biological Products - pharmacology Biological Products - therapeutic use biologics Blood pressure chemical entities Chemotherapy Constipation Diabetes Drug Approval - statistics & numerical data Drug Discovery Drug Industry - history Drug Industry - statistics & numerical data Drugs Enzymes FDA approval Glucagon Hemophilia History, 21st Century Humans Leukemia Multiple sclerosis Natural products Organic chemistry Peer review peptide Peptides Pharmaceutical industry Proteins Psoriasis Review Sepsis small molecules Structure-Activity Relationship United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 "harvest" have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small molecules.
ISSN:	1420-3049 1420-3049
DOI:	10.3390/molecules23030533